A phase i trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer

D. Magge, A. H. Zureikat, D. L. Bartlett, M. P. Holtzman, H. A. Choudry, J. H. Beumer, J. F. Pingpank, J. L. Holleran, S. Strychor, D. E. Cunningham, H. L. Jones, H. J. Zeh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Isolated hepatic perfusion (IHP) with melphalan is an established approach for patients with unresectable metastatic liver lesions. This study determined the safety and maximum tolerated dose (MTD) of 5-FU with oxaliplatin via IHP. Methods: Standard 3 × 3 Phase I design. Subjects with unresectable isolated CRC liver metastases scheduled for HAI pump were eligible. IHP used fixed-dose oxaliplatin with escalating 5-FU doses. Toxicity (CTCAE v 4.0) and response (RECIST), progression-free survival, and overall survival (OS) were assessed. Systemic and IHP plasma PK of 5-FU, anabolites, and platinum were determined. Results: All 12 patients had received ≥1 line of pre-IHP chemotherapy. There were 4 grade 3 serious adverse events (33.3 %) and 1 grade 4 event (8.3 %). Also, 2 dose-limiting toxicities occurred at DL2 at 300 mg/m2, resulting in expansion of DL1 at 200 mg/m2 5-FU, the eventual MTD. At 6-month follow-up, 9 patients (82 %) demonstrated partial response, while 2 (18 %) exhibited stable disease. Also, 64 % of patients demonstrated a >50 % decrease in CEA. The 1- and 2-year OS probabilities were 90.9 and 71.6 %, respectively, with median follow-up of 24 months. IHP exposures (AUC0-60 min) were 10.9 ± 4.5 μgPt h/mL, 49.3 ± 30.7 μg h/mL 5-FU (DL1), and 70.5 ± 35.5 μg h/mL 5-FU (DL2). Systemic exposure (AUC0-inf) relative to IHP exposure was negligible for both platinum (1.1 ± 1.5 %) and 5-FU (0.09 ± 0.10 %). Conclusions: The MTD for IHP was 200 mg/m2 5-FU with 40 mg/m 2 oxaliplatin. Systemic exposure to the agents was minimal during IHP. The response and survival observed warrants assessment in a larger phase II trial.

Original languageEnglish (US)
Pages (from-to)2180-2187
Number of pages8
JournalAnnals of Surgical Oncology
Volume20
Issue number7
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

oxaliplatin
Fluorouracil
Colorectal Neoplasms
Perfusion
Neoplasm Metastasis
Liver
Maximum Tolerated Dose
Platinum
Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

A phase i trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. / Magge, D.; Zureikat, A. H.; Bartlett, D. L.; Holtzman, M. P.; Choudry, H. A.; Beumer, J. H.; Pingpank, J. F.; Holleran, J. L.; Strychor, S.; Cunningham, D. E.; Jones, H. L.; Zeh, H. J.

In: Annals of Surgical Oncology, Vol. 20, No. 7, 01.07.2013, p. 2180-2187.

Research output: Contribution to journalArticle

Magge, D, Zureikat, AH, Bartlett, DL, Holtzman, MP, Choudry, HA, Beumer, JH, Pingpank, JF, Holleran, JL, Strychor, S, Cunningham, DE, Jones, HL & Zeh, HJ 2013, 'A phase i trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer', Annals of Surgical Oncology, vol. 20, no. 7, pp. 2180-2187. https://doi.org/10.1245/s10434-013-2960-3
Magge, D. ; Zureikat, A. H. ; Bartlett, D. L. ; Holtzman, M. P. ; Choudry, H. A. ; Beumer, J. H. ; Pingpank, J. F. ; Holleran, J. L. ; Strychor, S. ; Cunningham, D. E. ; Jones, H. L. ; Zeh, H. J. / A phase i trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. In: Annals of Surgical Oncology. 2013 ; Vol. 20, No. 7. pp. 2180-2187.
@article{a2033b4113aa4af098c27c90983b62aa,
title = "A phase i trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer",
abstract = "Background: Isolated hepatic perfusion (IHP) with melphalan is an established approach for patients with unresectable metastatic liver lesions. This study determined the safety and maximum tolerated dose (MTD) of 5-FU with oxaliplatin via IHP. Methods: Standard 3 × 3 Phase I design. Subjects with unresectable isolated CRC liver metastases scheduled for HAI pump were eligible. IHP used fixed-dose oxaliplatin with escalating 5-FU doses. Toxicity (CTCAE v 4.0) and response (RECIST), progression-free survival, and overall survival (OS) were assessed. Systemic and IHP plasma PK of 5-FU, anabolites, and platinum were determined. Results: All 12 patients had received ≥1 line of pre-IHP chemotherapy. There were 4 grade 3 serious adverse events (33.3 {\%}) and 1 grade 4 event (8.3 {\%}). Also, 2 dose-limiting toxicities occurred at DL2 at 300 mg/m2, resulting in expansion of DL1 at 200 mg/m2 5-FU, the eventual MTD. At 6-month follow-up, 9 patients (82 {\%}) demonstrated partial response, while 2 (18 {\%}) exhibited stable disease. Also, 64 {\%} of patients demonstrated a >50 {\%} decrease in CEA. The 1- and 2-year OS probabilities were 90.9 and 71.6 {\%}, respectively, with median follow-up of 24 months. IHP exposures (AUC0-60 min) were 10.9 ± 4.5 μgPt h/mL, 49.3 ± 30.7 μg h/mL 5-FU (DL1), and 70.5 ± 35.5 μg h/mL 5-FU (DL2). Systemic exposure (AUC0-inf) relative to IHP exposure was negligible for both platinum (1.1 ± 1.5 {\%}) and 5-FU (0.09 ± 0.10 {\%}). Conclusions: The MTD for IHP was 200 mg/m2 5-FU with 40 mg/m 2 oxaliplatin. Systemic exposure to the agents was minimal during IHP. The response and survival observed warrants assessment in a larger phase II trial.",
author = "D. Magge and Zureikat, {A. H.} and Bartlett, {D. L.} and Holtzman, {M. P.} and Choudry, {H. A.} and Beumer, {J. H.} and Pingpank, {J. F.} and Holleran, {J. L.} and S. Strychor and Cunningham, {D. E.} and Jones, {H. L.} and Zeh, {H. J.}",
year = "2013",
month = "7",
day = "1",
doi = "10.1245/s10434-013-2960-3",
language = "English (US)",
volume = "20",
pages = "2180--2187",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - A phase i trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer

AU - Magge, D.

AU - Zureikat, A. H.

AU - Bartlett, D. L.

AU - Holtzman, M. P.

AU - Choudry, H. A.

AU - Beumer, J. H.

AU - Pingpank, J. F.

AU - Holleran, J. L.

AU - Strychor, S.

AU - Cunningham, D. E.

AU - Jones, H. L.

AU - Zeh, H. J.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Background: Isolated hepatic perfusion (IHP) with melphalan is an established approach for patients with unresectable metastatic liver lesions. This study determined the safety and maximum tolerated dose (MTD) of 5-FU with oxaliplatin via IHP. Methods: Standard 3 × 3 Phase I design. Subjects with unresectable isolated CRC liver metastases scheduled for HAI pump were eligible. IHP used fixed-dose oxaliplatin with escalating 5-FU doses. Toxicity (CTCAE v 4.0) and response (RECIST), progression-free survival, and overall survival (OS) were assessed. Systemic and IHP plasma PK of 5-FU, anabolites, and platinum were determined. Results: All 12 patients had received ≥1 line of pre-IHP chemotherapy. There were 4 grade 3 serious adverse events (33.3 %) and 1 grade 4 event (8.3 %). Also, 2 dose-limiting toxicities occurred at DL2 at 300 mg/m2, resulting in expansion of DL1 at 200 mg/m2 5-FU, the eventual MTD. At 6-month follow-up, 9 patients (82 %) demonstrated partial response, while 2 (18 %) exhibited stable disease. Also, 64 % of patients demonstrated a >50 % decrease in CEA. The 1- and 2-year OS probabilities were 90.9 and 71.6 %, respectively, with median follow-up of 24 months. IHP exposures (AUC0-60 min) were 10.9 ± 4.5 μgPt h/mL, 49.3 ± 30.7 μg h/mL 5-FU (DL1), and 70.5 ± 35.5 μg h/mL 5-FU (DL2). Systemic exposure (AUC0-inf) relative to IHP exposure was negligible for both platinum (1.1 ± 1.5 %) and 5-FU (0.09 ± 0.10 %). Conclusions: The MTD for IHP was 200 mg/m2 5-FU with 40 mg/m 2 oxaliplatin. Systemic exposure to the agents was minimal during IHP. The response and survival observed warrants assessment in a larger phase II trial.

AB - Background: Isolated hepatic perfusion (IHP) with melphalan is an established approach for patients with unresectable metastatic liver lesions. This study determined the safety and maximum tolerated dose (MTD) of 5-FU with oxaliplatin via IHP. Methods: Standard 3 × 3 Phase I design. Subjects with unresectable isolated CRC liver metastases scheduled for HAI pump were eligible. IHP used fixed-dose oxaliplatin with escalating 5-FU doses. Toxicity (CTCAE v 4.0) and response (RECIST), progression-free survival, and overall survival (OS) were assessed. Systemic and IHP plasma PK of 5-FU, anabolites, and platinum were determined. Results: All 12 patients had received ≥1 line of pre-IHP chemotherapy. There were 4 grade 3 serious adverse events (33.3 %) and 1 grade 4 event (8.3 %). Also, 2 dose-limiting toxicities occurred at DL2 at 300 mg/m2, resulting in expansion of DL1 at 200 mg/m2 5-FU, the eventual MTD. At 6-month follow-up, 9 patients (82 %) demonstrated partial response, while 2 (18 %) exhibited stable disease. Also, 64 % of patients demonstrated a >50 % decrease in CEA. The 1- and 2-year OS probabilities were 90.9 and 71.6 %, respectively, with median follow-up of 24 months. IHP exposures (AUC0-60 min) were 10.9 ± 4.5 μgPt h/mL, 49.3 ± 30.7 μg h/mL 5-FU (DL1), and 70.5 ± 35.5 μg h/mL 5-FU (DL2). Systemic exposure (AUC0-inf) relative to IHP exposure was negligible for both platinum (1.1 ± 1.5 %) and 5-FU (0.09 ± 0.10 %). Conclusions: The MTD for IHP was 200 mg/m2 5-FU with 40 mg/m 2 oxaliplatin. Systemic exposure to the agents was minimal during IHP. The response and survival observed warrants assessment in a larger phase II trial.

UR - http://www.scopus.com/inward/record.url?scp=84878868949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878868949&partnerID=8YFLogxK

U2 - 10.1245/s10434-013-2960-3

DO - 10.1245/s10434-013-2960-3

M3 - Article

C2 - 23575907

AN - SCOPUS:84878868949

VL - 20

SP - 2180

EP - 2187

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 7

ER -